Management
Ola Sandborgh, CEO
Born: 1966 | Entered: 2023
Total shares with related parties and insurance: 37 500
Warrants A2 2021/2025: 0
Leading roles in different commercial, innovation and business development positions in companies such as Pfizer, Sanofi Pasteur MSD and, most recently, as Vice President Immunology & Specialty Care at Swedish Orphan Biovitrum (Sobi). Been leading global cross functional teams as well as coordinating partnerships with numerous of companies, contributing in several early to late-stage development projects and acquiring a significant experience within M&A ́s and DD ́s.
Ass. Professor Susanne Lindquist, Head of Research (CSO) and co-founder
Born: 1960 | Entered: 2010
Total shares with related parties and insurance: 324 696
Warrants A2 2021/2025: 0
Doctoral degree in microbiology and associate professor in pediatrics at Umeå University. More than 20 years of research work on BSSL and more than 27 original scientific articles. Susanne Lindquist has expertise in preclinical models for arthritis and other inflammatory diseases.
Dr. Pernilla Abrahamsson, COO
Born: 1972 | Entered: 2019
Total shares with related parties and insurance: 7 125
Warrants A2 2021/2025: 8 000
Doctoral degree in anaesthesiology and intensive care at Umeå University. Pernilla Abrahamsson founded MD Biomedical AB and developed advanced medical equipment (OnZurf Probe). The company was acquired by Senzime AB in 2015, where she worked until she started her job at Lipum.
Marina Norberg, CFO
Born: 1964 | Entered: 2021
Total shares with related parties and insurance: 16 300
Warrants A2 2021/2025: 4 000
Marina Norberg has experience of companies of different sizes in different industries. She has for many years been an approved auditor at PwC and worked as an authorized accounting consultant within Aspia AB. Marina has broad managerial experience and has also been part of the management team for Aspia.
Dr. Peter Hovstadius, CMO
Born: 1962 | Entered: 2024
Total shares with related parties and insurance: 5 755
Warrants A2 2021/2025: 0
Peter Hovstadius has a long career in both the pharmaceutical industry and academia. He has previously been in leading positions such as Chief Medical Officer at XNK Therapeutics, Chief Scientific Officer at Novartis and Research Director at MSD. Peter has through these roles, gained extensive experience in clinical drug development, and he has also been a driving force behind several important research and development initiatives in the pharmaceutical sector.